Compare Amylx Pharmaceuticals Inc (AMLX) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while SYSCO Corporation trades at $84.35 (market cap $40.09B). The key difference: SYSCO Corporation is far larger — about 20.2× Amylx Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SYY | |
|---|---|---|
Market Cap | $1.98B | $40.09B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $91.16 |
52-Week Low | $7.64 | $69.30 |
Enterprise Value | $1.70B | $53.57B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SYY trades at $83.83, up 2.19% today, near the consensus price target of $83.67. The stock shows bullish technical signals with strong moving averages and support at $81. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed slightly. Revenue grew to $81.37B in 2025, with net income of $1.83B. The company maintains a dividend with the next payment scheduled for July 2026.
Outlook remains positive with 60% analyst buy ratings and a high target of $86. Risks include margin pressure from rising costs and competitive threats. The transformative Restaurant Depot acquisition could drive long-term growth, but investors should monitor execution and macroeconomic impacts on food distribution demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
